TBD

Emma Lawton was diagnosed with Parkinson’s at the age of 29. Making it her mission to raise awareness about the condition and continue her life as she planned, Ms Lawton campaigns and shares her story on social media, published her own book on dealing with Parkinson’s and recently video blogged her life for 365 days.

In 2020, she did something new every day and blogged about it at www.thef---itlist.com to shine a light on the importance of investing in our own development and happiness. She featured in the BBC2 documentary: ‘The Big Life Fix’ where Microsoft’s Haiyan Zhang created a bespoke wearable device that allowed her to write and draw for the first time in years. Ms Lawton saw first hand the power of technology as an enabler. In 2015, she won the CharityComms Inspiring Communicator award for her fundraising for Parkinson’s. She is one of MT’s 35 women under 35 and has been dubbed ‘One to Watch’ by Wired Magazine. She was shortlisted for a Woman of the Future Award and is a 5-time TEDX speaker.

She’s shared a stage with the likes of Theresa May, Steph McGovern and Microsoft CEO Satya Nadella and has been interviewed on everything, from BBC Breakfast to late night radio shows. Ms Lawton is co-founder of tech startup More Human, a venture she started as part of the zinc.vc cohort. More Human is the AI events engine for communities, where the software turns everyone into a successful organiser of high- quality, well-attended events.

Diane Carozza has over 30 years of diverse experience in the pharmaceutical, technology and clinical services industries where she held various roles across Clinical Operations, R&D, R&D IS, Professional Services and Product Development. She joined Novartis in Aug 2023 as the Head of Vendor Program Strategy with a focus on embedding standardization and consistency across all Novartis drug programs by streamlining the vendor support model. Prior to Novartis, Ms Carozza led services delivery/product development teams at WCG, Medidata and InnovoCommerce. The first 2 decades of her career were largely spent in Clinical R&D and Clinical Operations at Pfizer and Allergan. Ms Carozza is a subject matter expert in study and site optimization, feasibility, and business process optimization relative to technologies that support clinical operations.

With over 15 years’ experience, Michael Ward, a Director in Syneos Health’s Patient Recruitment and Retention Management team, is leading a team of patient recruitment experts to develop and execute data-driven recruitment strategies that overcome the challenges and barriers seen on complex clinical trials that are struggling to meet recruitment timelines.

TBA

Michèle Bartlett is a psychotherapist and writer. Diagnosed with Parkinson’s disease six years ago, she has been an active contributor to a broad range of research initiatives. Drawing on her experiences of participating in a number of clinical trials and studies, she is a passionate advocate for integrating patient perspectives into research at all levels. She is Deputy Chair of the PPIE working group for the EJS ACT-PD initiative: developing the first multi-arm, multi-stage trial for potential disease modifying treatments for Parkinson’s disease in the UK. She is Co-Chair on behalf of PwP on the Critical Path for Parkinson’s Advisory Council for Patient-Centric Endpoints.

Faisal M. Khan, PhD is the Corporate Vice President for Artificial Intelligence and Analytics at Novo Nordisk. His team focuses on the applications of AI and data science throughout the drug development lifecycle. His interests focus on the intersections of data science, digital health, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedical analytics, including diagnostics, devices, clinical trials/therapeutics, and payers/insurance. Dr Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 100 published papers, abstracts, and patents on the applications of machine learning and artificial intelligence for healthcare and the life sciences.

Madelaine MacKay has 20 Years experience in the clinical research industry with a background in global project management and clinical management. For the past 8 years her focus has been on strategic implementation and operationalization of technology that incorporates research activities into the patient’s lifestyle. Currently at ICON, Ms MacKay is the head of the Platform Solution Enablement team within eClinical Development and Delivery that helps sites connect with their patients for modern clinical trials.

Ian Thompson has been with Ypsomed AG, formerly Disetronic AG, since 1995 in a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Since 2003 his main focus has been business development and new product innovation for Ypsomed Delivery Systems Platform Products: pen, autoinjector, wearable and connected injector technologies.